Dexcom stock holds near its yearly high after Q2 growth

Published on 09/23/2026 at 12:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dexcom stock closed at USD 89.17 on September 22, 2026, 3.7 percent below its yearly high. Q2 revenue rose 13.1 percent to USD 1.31 billion.

Fotorealistischer CGM-Sensor-Patch am Arm, klinisches Umfeld, Medizintechnik — Dexcom Inc. zeigt fotorealistischen CGM-Sensor am Unterarm für Anleger mit ISIN US2521311074 Medizintechnik, Illustration mit AI erstellt.

Dexcom Inc. (ISIN US2521311074) closed at USD 89.17 on Nasdaq on September 22, 2026, only 3.7 percent below its 52-week high of USD 92.59. The latest reported quarter delivered revenue of USD 1.31 billion, giving the stock a fundamental growth anchor as it trades near the upper end of its annual range.

Revenue rises to USD 1.31 billion

According to MarketBeat on September 22, 2026, Dexcom reported second-quarter 2026 revenue of USD 1.31 billion, up 13.1 percent from the year-earlier period. Revenue also exceeded the cited analyst estimate of USD 1.29 billion by USD 20 million.

The earnings comparison was similarly constructive: second-quarter 2026 earnings reached USD 0.70 per share versus consensus of USD 0.61 and the year-earlier figure of USD 0.48, according to MarketBeat on September 22, 2026. The USD 0.09 EPS beat over consensus adds a second quantified comparison beyond the 13.1 percent revenue growth.

Truist raises target to USD 102

Truist Securities maintained its Buy rating on September 18, 2026, and raised its Dexcom price target from USD 93 to USD 102, according to Ad-hoc-News. The increase of USD 9 equals 9.7 percent and places the new target USD 12.83 above the September 22 closing price.

The broader analyst range cited on September 21, 2026, extended from USD 79 to USD 115, with an average target of USD 94.48, according to Ad-hoc-News. That average was USD 5.31 above the closing price, while the range shows that valuation and execution remain material counterweights to the recent operating growth.

Stock stays below USD 92.59

Dexcom's market capitalization was USD 33.65 billion on September 22, 2026, and the 52-week range was USD 54.11 to USD 92.59. The stock stood USD 4.81 above its 50-day moving average of USD 84.36 and USD 15.78 above its 200-day moving average of USD 73.39, providing a dated technical reference without turning the observation into a trading recommendation.